Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Answer


    What this paper claims (in one line): GALNT11-directed O-glycans in LRP1’s short CR-linker regions selectively reshape ligand uptake—tau uptake drops without O-glycans, while Aβ uptake increases—and the authors map additional O-glycan–regulated CSF ligands.
    Primary evidence includes isogenic GALNT11 KO cell lines + CSF uptake proteomics + sLRP1 glyco-profiling + MD simulations.
    Paper:



     Long Answer


    Visual Paper Review: The Ligand Preference of LRP1 is Regulated by O-glycans

    Preprint (Oct 23, 2025):

    Mechanism map (as presented)

    GALNT11 adds O-glycans in LRP1 CR-linker regions; loss of GALNT11 does not change LRP1 surface levels/localization, but changes ligand uptake selectivity for neurological ligands.

    Selectivity: GALNT11 KO shifts tau vs Aβ uptake

    Values below are extracted from the paper text (percent changes in LRP1-dependent uptake under ΔT11 vs isogenic controls) and are therefore directional/approximate rather than universally transferable across ligands/preparations.

    O-glycan hyposialylation on soluble sLRP1 shifts under ΔT11

    The paper reports O-glycoprofiling of purified sLRP1 (with/without GALNT11) showing a ~3-fold decrease in non-sialylated core1/T and Tn, with a concomitant increase in mono- and di-sialylated core1 forms.

    MD simulations: sialylated core1 disrupts CR–RAP contact

    The paper’s MD section uses a CR5–CR6 + RAPd1 complex template (PDB 2fyl) and reports that non-sialylated core1/T can stack/interact with CR6 residues and engage RAPd1 contacts, while adding a sialic acid caps prevents those interactions (steric hindrance), leaving the linker disengaged.

    What’s strong vs what remains uncertain

    (Based strictly on content visible in the provided full-text excerpt.)
    Paper claim (testable) Main evidence shown Scientific status
    GALNT11 KO removes CR-linker O-glycans on LRP1 without majorly altering surface expression/localization Isogenic HEK models with GALNT11 KO; flow cytometry for surface staining; lectin probing (Jacalin) for undersialylated O-glycans Supported within the engineered cell context; still limited for in vivo tissue glycosylation and receptor biogenesis timing
    O-glycans differentially modulate uptake of tau vs Aβ Flow cytometric uptake with RAP competition; multiple tau forms (including hyperphosphorylated/phosphomimetic) and Aβ1-40/1-42 Directional effects are consistent across two cell models; magnitude may depend on ligand preparation/aggregation state and on cellular glycosylation/sialylation context
    CSF protein uptake discovery identifies LRP1 ligands whose uptake is O-glycan regulated LC-biotin CSF uptake + TMT-based differential MS quantification in HEK-LRP1 Act vs WT and vs Act-ΔT11; reports volcano plots and validated candidates (e.g., Hemopexin) Unbiased within the assay; pooled CSF and cell-system biology can mask individual variability or shift receptor–ligand accessibility
    Non-sialylated linker O-glycans can engage CR modules/RAP contacts; sialylation blocks MD simulations with core1/T vs sialyl-core1 capping on a linker residue in CR5-CR6:RAPd1 complex Mechanistic hypothesis supported by simulations; requires experimental structural/biochemical validation because force fields and starting conformations can bias outcomes

    Skeptical critique (epistemic humility)

    • Cell-model generality: The central mechanistic claim is supported mainly in engineered HEK and SH-SY5Y lines, which may not reproduce endogenous LRP1 biogenesis and glycosylation timing seen in relevant brain regions (e.g., choroid plexus epithelia). The paper itself frames the findings as mechanistically informative but calls for further in vivo validation.
    • Ligand-preparation confounds: The authors report a specific example where LC-biotinylated A2M shows GALNT11-dependent uptake changes while fluorescently labeled A2M does not, indicating that label chemistry/composition can influence effective uptake and apparent receptor usage.
    • Pathway partitioning ambiguity: Even though RAP is used as a competitive LRP1 antagonist, Aβ uptake is stated not to be fully suppressed by RAP—implying multiple uptake routes/transporters that could confound attribution of changes solely to LRP1–O-glycan affinity.
    • Glycoform specificity vs assay sensitivity: Lectin enrichment and glycoprofiling approaches can have biases: lectins report particular glycan motifs rather than full structural diversity, and beta-elimination-based glycomics may preferentially detect certain structural subsets. The paper explicitly notes limitations of glycoproteomics methods in providing comprehensive O-glycan structure information.
    • Simulation-to-biology leap: The MD component is a plausible mechanistic bridge, but force-field limitations and the discretized modeled glycoforms can lead to qualitative artifacts. This is a mechanistic hypothesis that should be tested by direct binding/structure methods and/or site-specific mutagenesis/glycoengineering.

    Data availability & reproducibility signals

    The paper reports mass spectrometry proteomics data deposition via PRIDE (PXD058370) and states that supporting data are available in the paper and supplementary files / upon request.


    Feedback:    

    Updated: March 30, 2026

     BGPT Paper Review


    Study Novelty

    90%

    It extends a known paradigm—GALNT11-driven O-glycosylation in LDLR/LRP linker regions affecting ligand binding—to LRP1 specifically, and pairs receptor glyco-engineering with (i) ligand uptake selectivity across tau/Aβ variants, (ii) unbiased CSF ligand discovery, and (iii) glyco-structure characterization + MD-supported mechanistic models.


    Scientific Quality

    80%

    High-quality multi-modal approach (isogenic KO + uptake assays + lectin/glyco-profiling + CSF LC-MS/MS + SPR + MD). Skeptical gaps: the excerpted text doesn’t quantify effect sizes for every claim, MD remains hypothesis-level, and Aβ uptake shows incomplete RAP competition—suggesting multiple routes. Still, the paper reports reproducibility signals (isogenic clones, multiple cell lines, and PRIDE deposition).


    Study Generality

    70%

    Mechanistic principle (site-specific O-glycans modulate ligand preference in large LDLR/LRP receptors) is generalizable across glycoprotein receptor families, but the specific ligand outcomes are context-dependent (cell line glycosylation state, ligand labeling/prep, and receptor isoforms).


    Study Usefulness

    90%

    Provides a concrete glyco-regulatory axis (GALNT11 → CR-linker O-glycans → LRP1 ligand preference) and an assay workflow for CSF ligand discovery tied to glycosylation. The ligand list (including hemopexin validation) can directly guide follow-up mechanistic studies.


    Study Reproducibility

    80%

    Methods are described in detail (cell engineering strategies, uptake assay workflow, LC-MS/MS workflow, glycoanalysis workflow, SPR and MD setup). PRIDE dataset deposition (PXD058370) supports verification. Remaining reproducibility risk: some glyco/MS steps require specialized expertise and parameter choices; the excerpt does not show full supplementary detail.


    Explanatory Depth

    80%

    Mechanistic integration is strong: hyposialylated linker O-glycan distributions + MD-predicted obstruction/engagement with RAP/CR modules provide a mechanistic bridge between glyco state and ligand uptake selectivity. However, direct experimental structural validation of the predicted contacts is not shown in the excerpt.


    🎁 Authors: Collect 500 Free Science Tokens (≈ $50.0 USD)

    Claim My Author Tokens

    Use for 125 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $50.0 USD)

     Analysis Wizard



    Parses the paper’s reported tau/Aβ uptake percentage shifts and generates a normalized bar chart (WT=1) while flagging any ligand where effect-size magnitude is not numerically provided.



     Hypothesis Graveyard


    The simplest “always increases uptake” model is unlikely because tau decreases while Aβ increases when GALNT11 is removed, indicating directionally opposite effects.


    A pure LRP1 expression-level effect is unlikely because the paper reports no major change in cell surface expression/localization under GALNT11 KO; ligand selectivity changes occur without gross receptor-level changes.

     Science Art


    Paper Review: The Ligand Preference of LRP1 is Regulated by O-glycans Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending